New international report examines the efficacy of “New GMOs” despite billions in investment in CRISPR and similar technologyBrussels / Bellingham, Wash., June 17, 2025 (GLOBE NEWSWIRE) -- As political ...

Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., the maker of a new gene-editing treatment, Lilly said on Tuesday.

Biotech firms focused on gene therapies traded higher after Eli Lilly (NYSE:LLY) agreed to acquire Boston-based gene-editing ...

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also ...